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Drug ExpenditureWe read with interest the article on the latest type of
performance-based managed entry agreement (MEA) very
recently introduced in Italy, the “Success Fee” [1]. Although we
regret that the authors did not cite our previous contributions on
the subject [2,3], we share their conclusion that MEAs in Italy
have led to triﬂing payback and were basically a failure from a
ﬁnancial point of view. Not only was payback minimal, but these
schemes are time-consuming and require costly investments to
manage all the forms [3].
In principle, we share the authors’ opinion that the scheme
seems to be a “step ahead” of the previous performance-based
contracts (i.e., risk-sharing and payment-by-result). As we noted
some years ago [2],
the Italian choice of requesting refunding for non-responders
instead of paying for responders … makes a major difference
from the Italian National Health Service viewpoint since each
hospital pharmacy buys the drug at full price in daily practice,
then non-responders have to be documented; otherwise any
undocumented non-responder will be paid as a success.
While awaiting ﬁnancial evidence on the ﬁrst example (pirfe-
nidone) described in the article, however, we have difﬁculty
sharing the authors’ optimistic view that this newborn scheme
will necessarily be a success and goes in the right direction.
Besides the major concern the authors raised on the still pending
issue of good management (“a failure … in delivering the
certiﬁcate to the company is interpreted as a successful treat-
ment and money has to be paid to the manufacturer”), which can
hardly be ruled out judging from the bad management of the
system so far [3], it should be added that performance-based
schemes have not added any value to clinical evidence in almost
a decade since their introduction. Going through the forms
referring to the patient’s clinical status (all available on the
Agenzia Italiana del Farmaco Web site) [4], it seems clear that
they do not provide any additional information useful for an
extended clinical assessment. So the information collected is
only a self-certiﬁed validation of appropriate prescription by the
physician [3].
We wonder, instead, whether the MEA trend should not
be directed toward cost-sharing agreements, as the Englishexperience of patient access schemes suggests [5]. Although
equivocal results from clinical trials have encouraged policy-
makers to put new drugs under performance-based contracts,
particularly anticancer drugs, these schemes contribute little to
robust clinical assessment in practice, given the absence of
randomization and the uncertain relationship between short-
term surrogate and hard end points. We certainly feel that simple
ﬁnancial-based contracts are arguably more efﬁcient as a means
for health services to reduce outlay on costly drugs and ensure
access for patients.
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